OPIANT PHARMACEUTICALS, INC. (OTCMKTS:OPNT) Files An 8-K Other Events

OPIANT PHARMACEUTICALS, INC. (OTCMKTS:OPNT) Files An 8-K Other Events
Item 8.01 Other Events.

Story continues below

On April 18, 2018, Opiant Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that it has been awarded a grant of approximately $7.4 million from the National Institutes of Health’s National Institute on Drug Abuse. The grant provides the Company with additional resources for the ongoing development of OPNT003 (intranasal nalmefene), a long-lasting opioid antagonist for the treatment of opioid overdose. The grant includes approximately $2.6 million to be funded for the period ending March 31, 2019, with the balance to be funded over the subsequent two years. A copy of the press release is attached hereto as Exhibit99.1 to this Current Report on Form8-Kand is incorporated herein by reference.

Item 9.01Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.Description

99.1

Press Release of Opiant Pharmaceuticals, Inc., dated April 18, 2018.


OPIANT PHARMACEUTICALS, INC. Exhibit
EX-99.1 2 opnt-pressreleaseapril2018.htm EXHIBIT 99.1 Exhibit Exhibit 99.1Opiant Pharmaceuticals Awarded Grant of Approximately $7.4 Million from the National Institutes of Health for Development of OPNT003,…
To view the full exhibit click here

About OPIANT PHARMACEUTICALS, INC. (OTCMKTS:OPNT)

Opiant Pharmaceuticals, Inc., formerly Lightlake Therapeutics, Inc., is a specialty pharmaceutical company. The Company develops pharmacological treatments for substance use, addictive and eating disorders. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdoses, which was conceived, licensed, developed and approved by the United States Food and Drug Administration (FDA). The Company’s pipeline of product candidates includes a treatment for Binge Eating Disorder (BED), a treatment for Bulimia Nervosa (BN), a treatment for Cocaine Use Disorder (CocUD) and a heroin vaccine. The Company also is focused on other treatment opportunities.

An ad to help with our costs